Paediatric antiretroviral use

Prezista (darunavir) has had its licence extended to include use in the treatment of HIV in antiretroviral-experienced children and adolescents over six years and weighing at least 20kg. Prezista should always be given in combination with low-dose ritonavir and other antiretrovirals.

View Prezista drug record

Further information: Janssen-Cilag

In addition, Aptivus (tipranavir) is now licensed for the treatment of HIV in highly pre-treated adolescents 12 years of age or older with virus resistant to multiple protease inhibitors. The drug should only be used as part of an active combination antiretroviral regimen in patients with no other therapeutic options.

View Aptivus drug record

Further information: Boehringer Ingelheim

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases